SSA
NKTR icon

Schonfeld Strategic Advisors’s Nektar Therapeutics NKTR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,667
Closed -$1.8M – 2409
2021
Q3 		$1.8M Buy
+6,667
New +$1.6M 0.02% 752

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's NKTR Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 8,063 shares — an estimated $580K sold.

Schonfeld Strategic Advisors first reported a position in NKTR in Q3 2016 and held it in 18 quarters. The position peaked at $2.62M in Q2 2025. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 8,063 Nektar Therapeutics shares in Q2 2026, an estimated $580K.
  • Schonfeld Strategic Advisors first reported a position in Nektar Therapeutics in Q3 2016 and held it in 18 quarters.
  • Schonfeld Strategic Advisors's Nektar Therapeutics position peaked at $2.62M in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.